Ranibizumab improves reading speed in patients with retinal vein occlusion
From Florida - A new report published in JAMA Ophthalmology examines reading speed outcomes in individuals with retinal vein occlusion treated with Lucentis. Researchers studied nearly 800 patients suffering from macular edema after branch retinal vein occlusion or central retinal vein occlusion. Participants were randomized to monthly sham injections, monthly ranibizumab 0.3 or monthly ranibizumab 0.5 mg. Researchers then assessed reading speed in the participants at 1,3 and 6 months post-injection. Results showed that individuals treated with ranibizumab were more likely to demonstrate reading speed improvements at 6 months than those who received sham injections.